Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


4 Pages (Click to Jump) V   1 2 3 4 >   
 
  
Reply to this topic

PEP, PEPLIN LIMITED
theadder
post Posted: Nov 11 2008, 10:31 PM
  Quote Post


Posts: 5,264
Thanks: 1136


another one today from the USPTO>>

United States Patent 7,449,492

Aylward , et al.
November 11, 2008

http://patft1.uspto.gov/netacgi/nph-Parser...111+AND+ICN/au)


Therapeutic agents--I


Abstract
The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects. The present invention further contemplates a method for the prophylaxis and/or treatment in mammalian, animal or avian subjects of infection or potential infection by pathogenic entities by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family of plants or their botanical or horticultural derivatives or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or in the form of a chemical fraction, sub-fraction, preparation or extract of the plant.



Inventors: Aylward; James Harrison (Indooroopilly, AU), Parsons; Peter Gordon (St. Lucia, AU), Suhrbier; Andreas (Bunya, AU), Turner; Kathleen Anne (Endeavour Hills, AU)
Assignee: Peplin Research Pty, Ltd. (Queensland, AU)

Appl. No.: 10/315,288


 
theadder
post Posted: Aug 12 2008, 02:36 PM
  Quote Post


Posts: 5,264
Thanks: 1136


From USPTO today a patent grant..

http://patft1.uspto.gov/netacgi/nph-Parser...812+AND+ACN/au)

United States Patent 7,410,656
Aylward
August 12, 2008

Anti-cancer compounds


Abstract
This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, andpharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.


Inventors: Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty. Ltd. (Fortitude Valley, AU)



 
chinaski
post Posted: Aug 8 2007, 02:46 PM
  Quote Post


Posts: 189


Looks like someone may appreciate PEP's potential :

Trading halt

The announcements concern proposals regarding certain significant corporate
transactions.

Until Friday morning ...........

 
Deejay
post Posted: Jul 15 2007, 12:10 PM
  Quote Post


Posts: 105
Thanks: 3


I am surprised at the lack of comment on PEP?? A superior Oz Bio, well advanced in clinical trials with a product with huge worldwide applications and demand, and the spin offs of the science are numerous. I guess its because they just get on with it, with little fanfare or drama.

Clinical trial results are due out later this month (they are always on time). PEP has hit a 1 year high and touched the 2 year high.

A long termer for me.

The chart is a weekly.

Cheers

DJ
Attached image(s)
Attached Image

 




--------------------
Remember, the decision and consequences on what you buy or sell is yours at the end of the day!. Do your own research and make up your own mind.
 
drrc
post Posted: Mar 12 2007, 05:43 AM
  Quote Post


Posts: 2,469
Thanks: 289



Drug company heads north

Liam Walsh

March 11, 2007 11:00pm
Article from: The Courier-Mail

A BRISBANE company developing a skin cancer treatment is eyeing growth outside of the skin-cancer hotbed that is Australia.

Peplin, dubbed the Australian biotechnology sector's "most valuable player" for 2006, has established a new office in a shiny San Francisco building.

Peplin is still Brisbane-based, but managing director Michael Aldridge this year relocated to the US bayside city's "biotechnology hub" and expects most new hires and growth will be in the US.

"If you want talented people, you've got to be based in the area where you've got people with a lot of experience developing drugs," he said.

Peplin is trialling PEP005, a compound derived from weed sap, with the aim of tapping a competitive skin cancer treatment market.

While its drug development has come a long way since listing in September 2000, share prices have not -- closing on Friday at 80, not far from the 55 level soon after the company's float.

That might improve, or fall, depending on the success or failure of major second-round trials this year.

While Peplin now has a US office Mr Aldridge said manufacturing, research and some early-stage work would remain in Australia.

Last year Peplin received a $40 million cash injection from investors and specialist fund MPM Capital, but clinical results were shaded by a bitter factory lawsuit.

Analysts at Bioshares said the investment was: "significant because it places Peplin in a strong position from which it can retain full rights to its lead compound and potentially access more funding through an even larger raising."

Mr Aldridge said MPM Capital did not interfere in the business. "When it comes to raising capital, hiring people, sourcing office space, tracking down consultants with specific expertise . . . they can be of assistance," he said.Bioshares also said results from another trial, showing clearance rates of around 70 per cent, were "impressive" and dubbed Peplin 2006's "most valuable player".

But Peplin was embroiled in a dispute over controlling a Southport factory that makes PEP005.

Within three months of the opening of the factory, last July, Peplin took legal action against Nutratec, the plant's builders and then operators.

Nutratec managing director Trevor Jordan writes in court documents of being "gutted and shattered" when told his family's services were no longer required.

Peplin complained in court documents of failures to comply with some operating procedures. But Nutratec countered it had no knowledge of any Peplin complaints and the factory had met an audit. When asked for proof of such failure, Peplin did not provide any evidence. The dispute settled out of court with Peplin gaining factory control.

Mr Aldridge said: "We're very pleased with how (the situation) worked out".

The company this month said it had recruited patients for a second round trial and was on track for phase III trials later this year.

Peplin had $39.5 million at the end of the last half and chalked up a loss of $10.4 million as it worked on its product.

Mr Aldridge said cash burn would increase as development ramped up.

Peplin has flagged having enough funds to deliver on its Phase II programs, the results of which are due this year.

ABN Amro Morgans has forecast a loss of $23.3 million this financial year.


from:

http://www.news.com.au/couriermail/story/0...94-3122,00.html

 
ozybuddy
post Posted: Feb 7 2007, 04:05 PM
  Quote Post


Posts: 182


important results expected soon : said to be Quarter 1 2007



--------------------
After a certain point, money is meaningless. It ceases to be the goal. The game is what counts.
- Aristotle Onassis
 

Featured Stock Stories





gungho
post Posted: Jul 12 2006, 02:05 PM
  Quote Post


Posts: 127
Thanks: 4


Good to see post rights recovery!

 
sierra
post Posted: May 25 2006, 10:03 AM
  Quote Post


Posts: 730
Thanks: 1


PEP

Skin cancer drug wins favour
By Rebecca Urban
May 25, 2006

http://www.theage.com.au/news/business/ski...8150325501.html



--------------------
Light travels faster than sound. This is why some
people appear bright until you hear them speak.
 
RADIO
post Posted: May 5 2006, 11:45 AM
  Quote Post


Posts: 3,268
Thanks: 9


user posted image

Recent ShareScene.com Radio Broadcast (Thu, 04 May 2006 3:00PM):

PEP - Skin Cancer Trial Update - Mr Michael Aldridge, Managing Director & CEO

N.B. ShareScene.com Radio can normally be accessed by the 'RADIO' link, top of every page.

-------------------------------------------------------------------------------------------------------------
ShareScene.com Radio delivers investor presentations from ASX listed companies. Keep up to date with the latest corporate dealings of the shares you follow. Hear news direct from the source. Listen to directors and investor relations mangers discuss their company, give investor updates and brief on current results. ShareScene.com Radio keeps you informed about company announcements and events, and provides you daily market wraps and industry discussions.
--------------------------------------------------------------------------------------------------------------

 
davesss
post Posted: May 1 2006, 03:57 PM
  Quote Post


Posts: 339
Thanks: 3


Any thoughts / interest on this release? I haven't followed PEP

ASX AND MEDIA RELEASE
Peplin announces positive results of phase IIa skin cancer trial
- Confirmed clearance of 71% of skin cancers
- PEP005 Topical demonstrates favourable safety profile
BRISBANE, Australia, 1 May 2006: Peplin Limited (ASX:PEP) today announced positive results from its Australian phase IIa clinical trial of its proprietary drug PEP005 Topical in superficial forms of basal cell carcinoma (sBCC) the most common form of skin cancer.
The phase IIa clinical trial achieved its objectives. Just two applications of PEP005 Topical (0.05%) gel on two consecutive days cleared 71% of sBCC tumours. This result was statistically significant (p=0.02). In addition PEP005 Topical gel had a favourable safety profile and was well tolerated. The majority of local skin responses reported were graded mild or moderate.
Managing Director & CEO Michael Aldridge said these positive results were a significant milestone for the company and of great interest to people with skin cancers in Australia and worldwide.
“The results of this Australian clinical trial exceeded our expectations,” Mr Aldridge said.
“While we achieved the primary purpose of the trial which was to establish the safety of the drug in treating non-melanoma skin cancers, we have shown that two consecutive days of treatment with PEP005 Topical gel can clear nearly three quarters of basal cell carcinomas, the most common form of skin cancer.
“Our next steps will be to undertake larger trials in Australia and the US starting later this year in order to make application to obtain regulatory approval to market the product as quickly as possible.”
Sydney dermatologist and a principal investigator, Dr Robert Rosen said this drug appears to be safe which was the primary purpose of the study and even at this early stage appeared effective in clearing superficial basal cell carcinomas.
“It is exciting that we are looking for answers for a condition that plagues Australia in particular and we seem to be on the right track at an early stage,” he said.

Brisbane dermatologist and also a principal investigator, Dr Greg Siller said these results were better than he anticipated for a drug so early in its clinical development.
“It appears to be as effective as other drugs which are already available but with only two applications,” Dr Siller said.
“It is a wonderful opportunity for Australian researchers to pioneer a new anti-cancer treatment.”
The sBCC phase IIa clinical trial was a double-blind, vehicle controlled, randomised, parallel group study at eight centres across Australia. PEP005 Topical gel in one of three concentrations or vehicle gel was applied to sBCC tumours on either day 1 and day 2 or day 1 and day 8; subjects were followed for 12 weeks; the tumour site was then completely excised and examined histologically for presence or absence of tumour tissue.
END

 
 


4 Pages (Click to Jump) V   1 2 3 4 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING